Cargando…

Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy

Despite modern treatment approaches, survival of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) remains low and it is difficult to identify patients who derive optimal benefit from treatment. We therefore analyzed which commonly available laboratory and cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Magnes, Teresa, Melchardt, Thomas, Weiss, Lukas, Mittermair, Christof, Neureiter, Daniel, Klieser, Eckhard, Gampenrieder, Simon, Moser, Gerhard, Gaggl, Alexander, Greil, Richard, Egle, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501656/ https://www.ncbi.nlm.nih.gov/pubmed/28686697 http://dx.doi.org/10.1371/journal.pone.0180995

Ejemplares similares

Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab
por: Magnes, T., et al.
Publicado: (2019)

CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer
por: Melchardt, Thomas, et al.
Publicado: (2015)

Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone: Analysis of the Austrian head and neck cancer registry of the AGMT
por: Magnes, Teresa, et al.
Publicado: (2021)

Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer
por: Huemer, Florian, et al.
Publicado: (2015)

Update on squamous cell carcinoma of the head and neck: ASCO annual meeting 2017
por: Magnes, Teresa, et al.
Publicado: (2017)

Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies
por: Magnes, Teresa, et al.
Publicado: (2021)

Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma
por: Magnes, Teresa, et al.
Publicado: (2021)

Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence
por: Magnes, T., et al.
Publicado: (2021)

NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients
por: Prochazka, Katharina T, et al.
Publicado: (2016)

Liver toxicity during temozolomide chemotherapy caused by Chinese herbs
por: Melchardt, Thomas, et al.
Publicado: (2014)

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL‐2 and/or BIM
por: Huemer, Florian, et al.
Publicado: (2019)

Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters
por: Schlick, Konstantin, et al.
Publicado: (2018)

C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling Overall Survival Prediction in Pancreatic Cancer Patients
por: Schlick, Konstantin, et al.
Publicado: (2019)

The Role of Neutrophilic Granulocytes in Philadelphia Chromosome Negative Myeloproliferative Neoplasms
por: Kiem, Dominik, et al.
Publicado: (2021)

Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial
por: Rinnerthaler, Gabriel, et al.
Publicado: (2020)

Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia: A case report
por: Huemer, Florian, et al.
Publicado: (2016)

Management of metastatic colorectal cancer in patients ≥70 years - a single center experience
por: Huemer, Florian, et al.
Publicado: (2023)

The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
por: Tejani, Mohamedtaki A, et al.
Publicado: (2010)

Treatment of Recurrent Metastatic Head and Neck Cancer: Focus on Cetuximab
por: Patel, Akshar N., et al.
Publicado: (2012)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020)

Two Cases of Pancytopenia with Coombs-Negative Hemolytic Anemia after Chimeric Antigen Receptor T-Cell Therapy
por: Kiem, Dominik, et al.
Publicado: (2021)

Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocol
por: Huemer, Florian, et al.
Publicado: (2022)

Induction chemotherapy with cetuximab, carboplatin and paclitaxel for the treatment of locally advanced squamous cell carcinoma of the head and neck
por: BAUMAN, JESSICA, et al.
Publicado: (2013)

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)

Complications of 5-azacytidine: Three cases of severe ischemic colitis in elderly patients with myelodysplastic syndrome
por: MELCHARDT, THOMAS, et al.
Publicado: (2013)

Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trial
por: Weiss, Lukas, et al.
Publicado: (2017)

Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones
por: Melchardt, Thomas, et al.
Publicado: (2016)

How I treat diffuse large B-cell lymphoma
por: Melchardt, T., et al.
Publicado: (2023)

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Taberna, Miren, et al.
Publicado: (2019)

Cost-Effectiveness of Adding Cetuximab to Platinum-Based Chemotherapy for First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer
por: Hannouf, Malek B., et al.
Publicado: (2012)

Cetuximab Plus Chemotherapy versus Chemotherapy Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis
por: Lang, Yitian, et al.
Publicado: (2020)

ASCO 2018 highlights: metastatic breast cancer
por: Rinnerthaler, Gabriel, et al.
Publicado: (2018)

Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer
por: Madoz-Gúrpide, Juan, et al.
Publicado: (2015)

Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK
por: Uozumi, Shinya, et al.
Publicado: (2018)

Weekly vs. 3-weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent/metastatic head and neck cancer
por: Geraghty, Leeann, et al.
Publicado: (2021)

SABCS 2016: systemic therapy for metastatic breast cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2017)

Cure in metastatic breast cancer
por: Westphal, Theresa, et al.
Publicado: (2018)

GERD—Barrett—Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers?
por: Illig, Romana, et al.
Publicado: (2013)

T cell exhaustion: from pathophysiological basics to tumor immunotherapy
por: Catakovic, Kemal, et al.
Publicado: (2017)

How We Treat Localized Rectal Cancer—An Institutional Paradigm for Total Neoadjuvant Therapy
por: Roeder, Falk, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_72pe2ftitro4soeab4hou3kh9l